Get the Stockscreener App
1.695
5.59%
0.085
Cardiff Oncology Inc stock is traded at $1.695, with a volume of 918.63K.
It is up +5.59% in the last 24 hours and up +7.59% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$1.61
Open:
$1.64
24h Volume:
918.63K
Relative Volume:
1.27
Market Cap:
$116.23M
Revenue:
$593.00K
Net Income/Loss:
$-45.85M
P/E Ratio:
-2.469
EPS:
-0.6865
Net Cash Flow:
$-37.97M
1W Performance:
+4.94%
1M Performance:
+7.59%
6M Performance:
-24.44%
1Y Performance:
-33.33%
1-Day Range:
$1.60
$1.705
1-Week Range:
$1.60
$1.75
52-Week Range:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.70 | 110.08M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
427.98 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
724.11 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.35 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.88 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.92 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
MSN Money - MSN
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
New Cardiff Oncology COO gets 400,000 stock options at $1.72 - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Mayo Clinic leukemia expert joins Cardiff webinar on CMML drug data - Stock Titan
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
CRDF (Cardiff Oncology Inc.) reports narrower than expected Q4 2025 loss, shares climb 4.29% on positive investor sentiment.Buyback Report - Cổng thông tin điện tử tỉnh Lào Cai
Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com - Investing.com India
Cardiff Oncology to present colorectal cancer trial data at ASCO - Investing.com
Cardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026 - Quiver Quantitative
Updated metastatic colon cancer data gets ASCO oral slot - Stock Titan
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Sahm
Cardiff Oncology presents preclinical data on cancer drug combo By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AA - GuruFocus
Cardiff Oncology presents preclinical data on cancer drug combo - Investing.com
Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options - Stock Titan
Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036 - Stock Titan
Cardiff Oncology (CRDF) CFO receives 486,650 options at $1.58 strike - Stock Titan
Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn
Cardiff Oncology Appoints Mani Mohindru as CEO and Expands Executive Team to Advance Cancer Drug Onvansertib - Minichart
Cardiff Oncology announces key leadership appointments to strengthen executive team for next phase of growth - marketscreener.com
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Bitget
Cardiff Oncology, Inc. Announces Management Appointments - marketscreener.com
Cardiff Oncology (CRDF) Appoints New Leadership Team - GuruFocus
Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026 - marketscreener.com
Cardiff Oncology, Inc. Appoints Mani Mohindru as Chief Executive Officer - marketscreener.com
Cardiff Oncology appoints new CEO, CFO and COO - TipRanks
Form 8-KCurrent report - ADVFN
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):